08 September 2020 : Clinical Research
Serum-Soluble ST2 Is a Novel Biomarker for Evaluating Left Atrial Low-Voltage Zone in Paroxysmal Atrial Fibrillation
Zefeng Wang1ACDE, Liting Cheng1BCD, Junmeng Zhang1AD, Zhuo Liang1CD, Ruiqing Dong2B, Fei Hang1B, Xinlu Wang1B, Ziyu Wang1B, Yongquan Wu1AD*, Jie Du3ADEDOI: 10.12659/MSM.926221
Med Sci Monit 2020; 26:e926221
Table 1 Comparison of baseline clinical materials.
| Group A (n=125) | Group B (n=52) | P valve | |
|---|---|---|---|
| Age, y | 56.4±9.4 | 62.4±9.3 | 0.002 |
| Male, n (%) | 87 (69.6%) | 36 (69.2%) | 0.961 |
| BMI, kg/m | 31.4±7.0 | 32.3±8.7 | 0.501 |
| AF duration, y | 24 (12, 48) | 24 (12, 48) | 0.789 |
| Hypertension, n (%) | 70 (56.0%) | 27 (51.9%) | 0.620 |
| Diabetes, n (%) | 24 (19.2%) | 8 (6.4%) | 0.548 |
| CHD, n (%) | 16 (12.8%) | 3 (5.8%) | 0.169 |
| ALT, U/L | 23.9±10.2 | 25.9±10.2 | 0.646 |
| AST, U/L | 24.1±8.7 | 22.7±5.8 | 0.284 |
| eGFR | 92.0±18.4 | 98.2±19.1 | 0.046 |
| CREA, mol/L | 72.0±16.8 | 69.1±14.8 | 0.272 |
| UA, mol/L | 343.4±100.9 | 340.7±92.0 | 0.865 |
| GLU, mmol/L | 5.9±1.6 | 5.2±0.8 | 0.093 |
| TCHO, mmol/L | 4.7±1.7 | 4.6±1.2 | 0.682 |
| LDL, mmol/L | 2.9±1.0 | 2.9±1.0 | 0.888 |
| HDL, mmol/L | 1.2±0.2 | 1.1±0.3 | 0.278 |
| TG, mmol/L | 1.8±1.1 | 1.7±0.9 | 0.494 |
| hs CRP, mg/L | 0.9 (0.6,2.1) | 1.0 (0.6,2.0) | 0.964 |
| LAAP-diameter, mm | 40.4±5.1 | 41.6±5.0 | 0.157 |
| EF,% | 61.6±6.0 | 60.3±5.5 | 0.078 |
| Normally distributed continuous variables are expressed as mean±standard deviation; non-uniformly distributed data are expressed as median (Q1, Q3); numbers are presented as number of patients (%). BMI – body mass index; AF – atrial fibrillation; CHD – coronary heart disease; ALT – alanine transaminase; AST – aspartate aminotransferase; eGFR – estimated glomerular filtration rate; CREA – creatinine; UA – uric acid; GLU – glucose; TCHO – total cholesterol; LDL – low-density lipoprotein; HDL – high-density lipoprotein; TG – triglyceride; LAAP-diameter – left atrial anteroposterior diameter; EF – ejection fraction. | |||